PONIARD PHARMACEUT COM USD0.02 (PARD)

0.06
0.00 (0.00)
OTC
Prev Close 0.06
Open 0.06
Day Low/High 0.06 / 0.06
52 Wk Low/High 0.04 / 0.21
Volume 374.00
Exchange OTC
Shares Outstanding 1.50B
Market Cap 3.30M
Div & Yield N.A. (N.A)

Latest News

5 Health Care Stocks With Upside

These health care stocks are scheduled to report their quarterly earnings today.

Poniard Pharmaceuticals CEO Discusses Q3 2010 Results - Earnings Call Transcript

Poniard Pharmaceuticals CEO Discusses Q3 2010 Results - Earnings Call Transcript

Poniard Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript

Poniard Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript

Stocks Under $5 With the Most Sell Ratings

Hovnanian and Blockbuster are among stocks under $5 with the most sell ratings from analysts.

Poniard Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript

Poniard Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript

Poniard, Xfone: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Wednesday's session.

Cell Therapeutics, Zoom Technologies: Midday Volume Plays

Several stocks trading near $5 were moving on above-average volume during Monday's session.

Medivation: Biotech Stock Mailbag

Medivation's (MDVN) Alzheimer's drug, Dimebon, failed an important drug trial. Hard lessons were learned, as explained in this bonus Mailbag.

Antigenics Files $100 Million Mixed Shelf: BioBuzz

Drug maker may try to raise money as approvals of its kidney cancer drug stall out.

New Gold, Poniard: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Monday's session.

Poniard Drug Safe, Less Effective: BioBuzz

Can Poniard attract a partner for a chemo drug that causes less nerve toxicity but may not help patients live longer?

Poniard, Blockbuster: Late Day Volume Plays

Several stocks trading near $5 were moving on above-average volume during Friday's session.

Biotech Stock Mailbag: Novelos Therapeutics

Biotech columnist Adam Feuerstein rolls out the year's first Mailbag, answering questions about Novelos and other stocks.

ARCA, FortuNet: Midday Volume Plays

Several stocks trading under $5 were moving on above-average volume during Monday's session.

Poniard Finds Cash to Keep Lights On: BioBuzz

Poniard faces a cash-crunch situation after a failed drug test last week.

Poniard, Netlist: Early Volume Plays

Several stocks trading under $5 were poised to move on above-average volume during Wednesday's session.

Poniard Rebounds On Picoplatin Colon Cancer Data

Poniard recovers part of Monday losses on data for picoplatin in colon cancer, and safety info

Poniard Plunges On Failure Of Picoplatin Study

Poniard Pharma drops more than 70 percent after lung cancer drug fails in late stage trial

Poniard's CEO Pulls a Belichick: BioBuzz

Risky late-game call puts Poniard in a deep financial hole.

A Closer Look at Cardium's Wound-Healing Drug: BioBuzz

Is it the drug or the gel that worked best in a phase II study?

Cell Therapeutics Lavishes Free Stock on Execs: BioBuzz

'Retention' bonus awarded to CEO Jim Bianco, his management team and directors.

Poniard Cancer Drug Misses Goal In Lung Cancer

Poniard Pharma says picoplatin did not improve survival in late stage study; shares tumble

Poniard Cancer Drug Fails Pivotal Study: BioBuzz

Lung cancer drug picoplatin doesn't prolong survival in phase III study.

Biotech Stock Mailbag: Poniard Predictions

Readers chime in on Poniard Pharmaceuticals, Chelsea Therapeutics, AMAG, Cel-Sci and Dendreon.

BMO Analyst Give Poniard 'Outperform' Rating

Poniard Pharmaceuticals shares rise as BMO Capital Markets analyst initiates with 'Outperform'

Four Must-See Charts: Biotech Stocks

These biotech stocks could be setting up to make big moves.

Biotech Calendar: More Key Clinical Trial Dates

Another quick and dirty guide to upcoming clinical trial dates for drug and biotech companies.

Top Takes From RealMoney

Here's what some of our market pros are saying and playing.